Welcome to our dedicated page for Hims & Hers Health news (Ticker: HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.
Hims & Hers Health, Inc. (NYSE: HIMS) is a health and wellness platform that regularly issues news about its digital care offerings, new specialties, and international growth. Company press releases highlight how the Hims and Hers brands use technology to connect customers with personalized care, with updates that span weight management, women’s health, labs and diagnostics, and broader platform developments.
Recent news has focused heavily on weight loss and metabolic health. Hims & Hers has launched a comprehensive Weight Loss Programme in the UK, including the official introduction of the Hers platform there, giving eligible women access to doctor-designed GLP‑1 treatment plans and holistic support for nutrition, movement, and sleep. In Canada, the company is entering the market through the acquisition of Livewell, a digital health platform focused on weight loss treatment, with plans to roll out an accessible, comprehensive weight loss program for Canadian customers.
Another key news theme is women’s health. The Hers platform has introduced a menopause and perimenopause specialty that offers eligible women access to treatment plans tailored to their health history and preferences, including prescription options such as estradiol and progesterone when deemed appropriate by licensed providers. News coverage also includes the launch of Labs, a testing experience that measures biomarkers across areas like heart health, metabolism, hormones, inflammation, and stress, pairing results with doctor-developed action plans.
Investors and followers of HIMS news will also see announcements about strategic acquisitions, such as the definitive agreement to acquire YourBio Health and its virtually painless TAP blood sampling technology, as well as corporate updates like share repurchase authorizations, financial results, leadership appointments, and facility investments. This news page aggregates these developments so readers can monitor how Hims & Hers is expanding its digital health platform, adding new capabilities, and executing its strategy across the United States, Europe, and Canada.
Hims & Hers Health, Inc. (NYSE:HIMS) announced participation in the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. CEO Andrew Dudum and Chief Medical Officer Patrick Carroll will hold one-on-one meetings and a live webcast of Dudum's fireside chat is scheduled for 4:20 PM ET. The webcast will be accessible on Hims & Hers investor relations website and archived for 90 days. The company, founded in November 2017, offers a multi-specialty telehealth platform providing access to healthcare for various conditions across the U.S.
Hims & Hers (NYSE: HIMS) and Walgreens (NASDAQ: WBA) have announced a collaboration to enhance access to health and wellness solutions. Hims & Hers products, including supplements and sexual health offerings, will be available at over 7,000 Walgreens locations and on walgreens.com starting early November. This partnership aims to destigmatize health topics and support Hims & Hers' goal of mass market accessibility, providing trusted health products to consumers in the U.S.
Hims & Hers has launched the Climax Delay Wipes, a non-prescription treatment aimed at addressing premature ejaculation, which affects nearly 1 in 4 men. These single-use benzocaine wipes are designed to help men maintain erections and gain better control over their climax. This addition complements existing products like Climax Delay Spray and various prescription options available through telehealth consultations. CEO Andrew Dudum emphasized the company's mission to enhance personalized healthcare access, providing a range of solutions for sexual health.
Hims & Hers Health, a telehealth platform, will release its fiscal third quarter financial results on November 10, 2021, after the market closes. A conference call is scheduled for 5:00 p.m. E.T. The company connects consumers to healthcare professionals for a variety of medical concerns, including primary care and mental health. Hims & Hers operates across all 50 states and Washington, D.C., providing accessible healthcare solutions. Investors and media are invited to access the live call or listen to a replay online.
Regis Corporation (NYSE:RGS) announces John Davi as the new Chief Technology Officer, aiming to enhance its Opensalon ecosystem. With over 20 years in technology, Davi has previously worked with BriteCore and MINDBODY, and has experience in artificial intelligence and media solutions. His expertise is expected to drive technology development and improve franchisee support. Regis operates the world's largest franchise network of hair salons, with 5,917 locations globally as of June 30, 2021.
Hims & Hers Health, Inc. (NYSE: HIMS) has partnered with The Vitamin Shoppe to expand the availability of its haircare products. Starting now, customers can purchase Hims & Hers products both online and in over 280 Vitamin Shoppe locations. This partnership will initially focus on haircare solutions, including popular items such as Minoxidil treatments and biotin gummies, with plans for future expansion into other product lines. The collaboration aims to enhance consumer access to personalized health and wellness solutions.
Hims & Hers Health has launched new skincare offerings, including the Hims Overnight Anti-Aging Duo and Hers Clear Skin System. The Overnight Anti-Aging Duo features a customizable prescription Anti-Aging Cream and a nonprescription Goodnight Wrinkle Cream targeted at wrinkles and sun damage. The Hers Clear Skin System offers a customizable prescription acne cream alongside hydrating cleanser and moisturizer. Both products emphasize individual customization through consultations with healthcare providers, enhancing the company's telehealth service model.
Hims & Hers Health has launched a new D-Mannose dietary supplement, aimed at improving urinary tract health for women. Available on ForHers.com, this product comes in single-serve packets that combine D-Mannose, vitamins, and electrolytes. The initiative addresses a significant health need, as 30-40% of women experiencing a urinary tract infection will have another within six months. This highlights the company's commitment to providing holistic health solutions that are accessible and user-friendly.
Hims & Hers announced a strategic partnership with REVOLVE, allowing a diverse range of health and wellness products to be sold on REVOLVE.com. This collaboration targets Millennial and Generation Z consumers by offering affordable skincare, hair care, sleep supplements, and sexual health products. Both companies aim to enhance their brands' appeal in the consumer health and fashion sectors. This partnership follows Hims & Hers' role as the exclusive wellness partner at REVOLVE's New York Fashion Week events, further solidifying their joint brand outreach.
Hims & Hers Health, Inc. (NYSE:HIMS) announced participation in two significant conferences. The first is Citi's 2021 Virtual Global Technology Conference from September 13-15, with individual investor meetings on September 14. The second is the Raymond James Consumer Conference on September 14, featuring a live webcast with CEO Andrew Dudum at 4:20 PM ET. Hims & Hers, founded in November 2017, is a telehealth platform connecting consumers to healthcare professionals across the U.S., offering a range of health and wellness products.